Pertussis vaccines: Position paper of Indian Academy of Pediatrics (IAP)

Indian Pediatrics

Volumn 50, Issue 11, 2013, Pages 1001-1009

  Vashishtha, Vipin M ^a   Bansal, C P ^a   Gupta, Sailesh G ^a  

^a Mangla Hospital and Research Center   (India)

Author keywords

Acellular pertussis vaccines; Indian Academy of Pediatrics; Pertussis; Recommendations; Whole cell pertussis vaccines

Indexed keywords

ACELLULAR VACCINE; PERTUSSIS VACCINE;

ARTICLE; DRUG EFFICACY; DRUG PREFERENCE; HEALTH CARE PLANNING; HUMAN; IMMUNIZATION; INDIA; INDUSTRIALIZATION; INFANT DISEASE; MATERNAL CARE; PERTUSSIS; PREGNANT WOMAN; PROTECTION; TREATMENT DURATION; WHOLE CELL;

ACADEMIES AND INSTITUTES; ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INDIA; PEDIATRICS; PERTUSSIS VACCINE; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; YOUNG ADULT;

EID: 84890542567     PISSN: 00196061     EISSN: 09747559     Source Type: Journal    
DOI: 10.1007/s13312-013-0274-y     Document Type: Article

References (57)

1. Jackson DW, Rohani P. Perplexities of pertussis: recent global epidemiological trends and their potential causes. Epidemiol Infect. 2013 Jan 16:1-13. [Epub ahead of print]
2. Centers for Disease Control and Prevention (CDC). Pertussis. Surveillance and Reporting. Trends. Available from: www.cdc.gov/pertussis/surv-reporting. html. Accessed on March 28, 2013.
3. Winter K, Harriman K, Zipprich J, Schechter R, Talarico J, Watt J, et al. California pertussis epidemic, 2010. J Pediatr. 2012;161:1091-1096.
4. Centers for Disease Control and Prevention (CDC). Pertussis epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep. 2012; 61:517-522.
5. European Center for Disease Prevention and Control-Annual epidemiological report 2012. Available from: http://ecdc.europa.eu/en/publications/ Publications/Annual-Epidemiological-Report-2012.pdf. Accessed on March 29, 2013.
6. Public Health England. Table: whooping cough (pertussis) laboratory reports in England and Wales by region and age group, 2008-2011 (confirmed by culture, PCR and/or serology). Available at: http://www.hpa.org.uk/webw/ HPAweb&HPAwebStandard/HPAweb-C/1317132184294. Accessed on April 4, 2013.
7. Gabutti G, Rota MC. Pertussis: a review of disease epidemiology worldwide and in Italy. Int J Environ Res Public Health. 2012;9:4626-4638.
8. Libster R, Edwards KM. Re-emergence of pertussis: what are the solutions? Expert Rev Vaccines. 2012;11:1331-1346.
9. Government of Western Australia, Department of Health. Ongoing pertussis epidemic in Western Australia. Available from: http://www.health.wa.gov.au/ diseasewatch/vol16-issue1/Ongoing-pertussis-epidemic-in-Western-Australia.cfm. Accessed on March 31, 2013.
10. New Zealand Public Health Surveillance Report; September 2012. Available from: http://www.surv.esr.cri.nz/PDF-surveillance/NZPHSR/2012/NZPHSR2012Sep.pdf. Accessed on March 31, 2013.
11. Mughal A, Kazi YF, Bukhari HA, Ali M. Pertussis resurgence among vaccinated children in Khairpur, Sindh, Pakistan. Public Health. 2012; 126:518-522.
12. Bokhari H, Said F, Syed MA, Mughal A, Kazi YF, Kallonen T, et al. Molecular typing of Bordetella parapertussis isolates circulating in Pakistan. FEMS Immunol Med Microbiol. 2011; 63:373-380.
13. Cherry JD. Epidemic pertussis in 2012-the resurgence of a vaccine-preventable disease. N Engl J Med. 2012;367:785-787.
14. Octavia S, Sintchenko V, Gilbert GL, Lawrence A, Keil AD, Hogg G, et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J Infect Dis. 2012; 205:1220-1224.
15. Cherry JD. Why do pertussis vaccines fail? Pediatrics. 2012; 129:968-970.
16. Clark TA, Messonnier NE, Hadler SC. Pertussis control: time for something new? Trends Microbiol. 2012; 20: 211-213.
17. Mascart F, Hainaut M, Peltier A, Verscheure V, Levy J, Locht C. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine. 2007;25:391-398.
18. Cherry JD, Heininger U, Richards DM, Storsaeter J, Gustafsson L, Ljungman M, et al. Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol. 2010; 17:741-747.
19. Edwards KM, Decker MD. Pertussis vaccines. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines, 5th ed. Philadelphia; Saunders; 2008:467-517.
20. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. Br Med J (Clin Res Ed). 1988; 296:612-614.
21. Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med. 1996;334:349-355.
22. Gustafsson L, Hessel L, Storsaeter J, Olin P. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics. 2006; 118:978-984.
23. Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics. 2005; 116:e285-294.
24. Salmaso S, Mastrantonio P, Tozzi AE, Stefanelli P, Anemona A, Ciofidegli Atti ML, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001; 108:E81.
25. Mills KHG. Immunity to Bordetella pertussis. Microbes Infect. 2001;3: 655-677.
26. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012; 367:1012-1019.
27. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J. 2005;24(5 Suppl):S58-S61.
28. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis. 2012; 54:1730-1735.
29. Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012; 308:2126-2132.
30. Rendi-Wagner P, Kundi M, Mikolasek A, Vecsei A, Fruhwirth M, Kollaritsch H. Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine. Vaccine. 2006; 24:5960-5965.
31. Lacombe K, Yam A, Simondon K, Pinchinat S, Simondon F. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine 2004; 23:623-628.
32. Wei SC, Tatti K, Cushing K, Rosen J, Brown K, Cassiday P, et al. Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis. Clin Infect Dis. 2010; 51:315-321.
33. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis. 2013; 56:1248-1254.
34. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Number and order of whole cell pertussis vaccines in infancy and disease protection. JAMA. 2012; 308:454-456.
35. Liko J, Robison SG, Cieslak PR. Priming with whole-cell versus acellular pertussis vaccine. N Engl J Med. 2013; 368:581-582.
36. Pertussis vaccines: WHO position paper. October 2010. Wkly Epidemiol Rec. 2010; 85: 385-400.
37. Diphtheria, Tetanus and Pertussis Vaccines. In: Yewale V, Choudhury P, Thacker N, eds. IAP Guide Book on Immunization. Mumbai: Indian Academy of Pediatrics; 2009-10: 56-64.
38. Kendrick PL, Eldering G, Dixon MK, Misner J. Mouse protection tests in the study of pertussis vaccine; a comparative series using the intracerebral route for challenge. Am J Public Health Nations Health. 1947; 37:803-810.
39. WHO. Guidelines for the production and control of the acellular pertussis component of monovalent or combined vaccines. WHO Technical Report Series No. 878, 1998. Available from: http://www.who.int/biologicals/publications/trs/ areas/vaccines/acellular-pertussis/WHO-TRS-878-A2.pdf. Accessed on April 7, 2013.
40. Jefferson T, Rudin M, DiPietrantonj C. Systematic review of the effects of pertussis vaccines in children. Vaccine. 2003; 21:2003-2014.
41. Zhang L, Prietsch SO, Axelsson I, Halperin SA. Acellular vaccines for preventing whooping cough in children. Cochrane Database Syst Rev. 2012; 3:CD001478.
42. Stokley S, Cohn A, Dorell C, Hariri S, Yankey D, Messonnier N, et al. Adolescent vaccination-coverage levels in the United States: 2006-2009. Pediatrics. 2011; 128:1078-1086.
43. CDC, Advisory Committee on Immunization Practices (ACIP). Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-34.
44. Castagnini L, Healy MC, Rench MA, Wootton SH, Munoz FM, Baker CJ. Impact of maternal postpartum tetanus diptheria toxoids and acellular pertussis immunization of infant pertussis infection. Clin Inf Dis. 2012;54:78-84.
45. Healy CM, Baker CJ. Prospects for prevention of childhood infections by maternal immunization. Curr Opin Infect Dis. 2006;19: 271-276.
46. CDC. Prevention of pertussis, tetanus and diphtheria among pregnant and postpartum women and their infants. Morb and Mort Wkly Rep. 2008; 57:1-51.
47. CDC. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Weekly Rep. 2011;60:1424-1426.
48. Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol. 2011; 204:334.e1-334.e5.
49. Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis. 1990;161:487-492.
50. Englund JA, Anderson EL, Reed GF, Decker MD, Edwards KM, Pichichero ME, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics. 1995;96:580-584.
51. Hardy-Fairbanks AJ, Pan SJ, Decker MD, Johnson DR, Greenberg DP, Kirkland KB, et al. Immune responses in infants whose mothers received tdap vaccine during pregnancy. Pediatr Infect Dis J. 2013 Jun 24. [Epub ahead of print]
52. Libster R, Edwards KM. How can we best prevent pertussis in infants? Clin Infect Dis. 2012; 54:85-87.
53. White OJ, Rowe J, Richmond P, Marshall H, McIntyre P, Wood N, et al. Th2-polarisation of cellular immune memory to neonatal pertussis vaccination. Vaccine. 2010;28:2648-2652.
54. Knuf M, Schmitt HJ, Wolter J, Schuerman L, Jacquet JM, Kieninger D, et al. Neonatal vaccination with an acellular pertussis vaccine accelerates the acquisition of pertussis antibodies in infants. J Pediatr. 2008;.52:655-660, 660.e1.
55. Wood N, McIntyre P, Marshall H, Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J. 2010;29:209-215.
56. National Health Profile (NHP) of India - 2011, Government of India, Central Bureau of Health Intelligence, DGHS. Ministry of Health and Family Welfare. Available from: http://cbhidghs.nic.in/writereaddata/mainlinkFile/ 08%20Health%20Status%20%20Indicators%20%202011.pdf. Accessed on March 24, 2013.
57. UNICEF Coverage Evaluation survey, 2009 National Fact Sheet. Available from: http://www.unicef.org/india/National-Fact-Sheet-CES-2009.pdf. Accessed on March 27, 2013.